Coagulation Factor XI
EstablishedFactor XI deficiency is a mild bleeding disorder; factor XI inhibitor drugs are a major, still-unsettled anticoagulant research area.
Factor XI helps blood clot. People missing it usually bleed only mildly. Separately, new drugs that block factor XI were designed to be safer blood thinners, but results have been mixed — failing in some trials, succeeding in others — so the final verdict on these drugs is still being written.
Factor XI is a clotting protein whose deficiency causes a generally mild bleeding disorder, but which has become the focus of intense pharmaceutical interest as a target for a new generation of anticoagulants aiming to prevent clots with less bleeding risk than existing drugs.
Hereditary Factor XI deficiency (common in Ashkenazi Jewish populations) causes variable, often mild bleeding tendency; separately, and far more prominently in current research, factor XI inhibitor drugs are being tested as safer alternatives to standard anticoagulants.
Deficiency diagnosed via specific factor XI assay with prolonged aPTT; the drug-development story involves oral factor XI inhibitors (asundexian, milvexian) in large clinical trials for stroke and atrial fibrillation prevention.
Results for factor XI inhibitors have been a genuine rollercoaster: milvexian failed in acute coronary syndrome (stopped early for futility), asundexian failed against apixaban in atrial fibrillation (nearly 4x higher stroke risk in the 2024 OCEANIC-AF trial), but asundexian then showed positive results for secondary stroke prevention after non-cardioembolic stroke (reported early 2026) — this remains a very much unsettled, actively-evolving area.
One of the most actively-evolving areas in current cardiology/hematology drug development, with mixed trial results through 2026.
- Medscape. (2025). Anti-Factor XI Anticoagulants: Breakthrough or Bust?
- NEJM. (2024). Asundexian versus Apixaban in Patients with Atrial Fibrillation.
- Medscape. (2026). Factor XI Inhibitors: Will Third Time Be the CV Charm?